RESEARCH

Supply Chain: INDETERMINATE — sources diverge sharply on China's sole-source KSM exposure in U.S. pharma APIs

Supply Chain · 2026-05-24 14:14

The Delta Engine checked how prominently five independent sources feature the claim that China is the sole supplier of at least one key starting material for 37–41% of all APIs approved for the U.S. market. Sources ranged from the U.S. Pharmacopeia — which treats this as a headline policy finding — to industry trade publications that frame it as one risk factor among many. The engine returned deltaFinal = 0.344, well above the 0.05 threshold, flagging INDETERMINATE: the claim is factually consistent across sources but the weight each assigns it varies by a factor of nearly 1.4×.

Findings

The U.S. Pharmacopeia's Medicines Supply Map found China is the sole supplier of at least one KSM for 679 APIs, covering 37% of all APIs in their analysis — a direct single-point-of-failure risk for more than a third of the U.S. formulary.
Brookings Institution's analysis independently puts the sole-source KSM exposure at ~41%, slightly higher than USP, reflecting different API universe definitions — both numbers point to the same structural problem.
India, which fills 90% of U.S. generic prescriptions by volume, itself depends on China for ~70% of bulk drug and intermediate imports, meaning a Chinese supply disruption cascades through both direct and indirect channels.
Policy sources (USP, Brookings) score this claim at 85–92 prominence; industry sources (LGM Pharma, Coalition for a Prosperous America) score 65–70 — the divergence reflects not factual disagreement but a gap in how urgently different sectors communicate this risk to their audiences.

Delta Engine result

↔ Divergence Detected — Δ 0.344 (threshold 0.05)